Manish R Patel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8499144/publications.pdf

Version: 2024-02-01

		430874	233421
49	2,581	18	45
papers	citations	h-index	g-index

49	49	49	4325
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Avelumab, an Antiâ€“Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. Journal of Clinical Oncology, 2017, 35, 2117-2124.	1.6	538
2	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncology, The, 2018, 19, 51-64.	10.7	491
3	ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncology, The, 2018, 19, 694-704.	10.7	310
4	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 261-270.	10.7	303
5	Oncolytic virus therapy for cancer: the first wave ofÂtranslational clinical trials. Translational Research, 2013, 161, 355-364.	5.0	87
6	Vesicular stomatitis virus expressing interferon-Î² is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget, 2015, 6, 33165-33177.	1.8	87
7	Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapyâ€“ a report of two cases. , 2016, 4, 80.		80
8	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusionâ€“Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 1253-1263.	1.6	74
9	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical Cancer Research, 2022, 28, 1302-1312.	7.0	74
10	JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Therapy, 2019, 26, 411-418.	4.6	60
11	Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.. Journal of Clinical Oncology, 2020, 38, 3605-3605.	1.6	33
12	Targeting Eukaryotic Translation in Mesothelioma Cells with an eIF4E-Specific Antisense Oligonucleotide. PLoS ONE, 2013, 8, e81669.	2.5	32
13	Ras Pathway Activation in Malignant Mesothelioma. Journal of Thoracic Oncology, 2007, 2, 789-795.	1.1	31
14	Malnutrition Identified by the Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition Consensus Criteria and Other Bedside Tools Is Highly Prevalent in a Sample of Individuals Undergoing Treatment for Head and Neck Cancer. Journal of Parenteral and Enteral Nutrition, 2016, 42, 014860711667226.	2.6	29
15	Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. Investigational New Drugs, 2010, 28, 20-25.	2.6	28
16	Measles Vaccine Strains for Virotherapy of Nonâ€“Small-Cell Lung Carcinoma. Journal of Thoracic Oncology, 2014, 9, 1101-1110.	1.1	27
17	Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma. Genes and Cancer, 2015, 6, 144-152.	1.9	27
18	Nutrition Status and Healthâ€Related Quality of Life Among Outpatients With Advanced Head and Neck Cancer. Nutrition in Clinical Practice, 2020, 35, 1129-1137.	2.4	24

#	Article	IF	Citations
19	Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. Investigational New Drugs, 2014, 32, 598-603.	2.6	21
20	Effects of Insulin-Like Growth Factor-1 Receptor Inhibition in Mesothelioma. Annals of Thoracic Surgery, 2006, 82, 996-1002.	1.3	19
21	Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis. Investigational New Drugs, 2012, 30, 1443-1448.	2.6	15
22	Endometrial Metastasis of Lung Adenocarcinoma: A Report of Two Cases. American Journal of Case Reports, 2015, 16, 296-299.	0.8	15
23	A review of avelumab in locally advanced and metastatic bladder cancer. Therapeutic Advances in Urology, 2019, 11, 175628721882348.	2.0	15
24	Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus Expressing Interferon-Î² in Preclinical Models of Non-Small Cell Lung Cancer. Translational Oncology, 2020, 13, 100782.	3.7	14
25	Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110044.	1.3	13
26	Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC. Journal of Thoracic Oncology, 2013, 8, 1142-1147.	1.1	12
27	Immune Checkpoint Inhibitors in ROS1-Rearranged Nonâ€“Small Cell Lung Cancer: A Report of Two Cases. Journal of Thoracic Oncology, 2019, 14, e165-e167.	1.1	12
28	Impact of antibiotics and proton pump inhibitors on clinical outcomes of immune check point blockers in advanced non-small cell lung cancers and metastatic renal cell cancer.. Journal of Clinical Oncology, 2019, 37, e20520-e20520.	1.6	12
29	Viroimmunotherapy of Thoracic Cancers. Biomedicines, 2017, 5, 2.	3.2	11
30	Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNÎ²-NIS (VV1) oncolytic virus in patients with refractory solid tumors.. Journal of Clinical Oncology, 2020, 38, 3090-3090.	1.6	10
31	4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma. Investigational New Drugs, 2018, 36, 217-229.	2.6	9
32	Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer. Cancer Gene Therapy, 2019, 26, 157-165.	4.6	9
33	The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 2916.	4.1	8
34	Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation. International Journal of Oncology, 2012, 40, 577-82.	3.3	7
35	Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma. Oncotarget, 2017, 8, 63096-63109.	1.8	7
36	Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma. Cancer Chemotherapy and Pharmacology, 2020, 85, 425-432.	2.3	6

#	Article	IF	Citations
37	4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer. Investigational New Drugs, 2021, 39, 636-643.	2.6	5
38	Cytomegalovirus infection in malignant pleural mesothelioma. PLoS ONE, 2021, 16, e0254136.	2.5	4
39	Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives. Anticancer Research, 2015, 35, 5211-7.	1.1	4
40	Genetic Engineering of Oncolytic Viruses for Cancer Therapy. , 2015, , 261-279.		3
41	Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review. Case Reports in Oncological Medicine, 2020, 2020, 1-6.	0.3	3
42	957â€…NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study. , 2021, 9, A1007-A1007.		3
43	Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC. Lung Cancer Management, 2022, 11, LMT54.	1.5	3
44	An Absolute Obstacle: Cardiac Metastasis of Synovial Sarcoma. American Journal of Medicine, 2014, 127, 390-392.	1.5	2
45	Immunotherapy for thoracic oncology gone viral. Immunotherapy, 2018, 10, 383-390.	2.0	1
46	ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine.. Journal of Clinical Oncology, 2018, 36, 6052-6052.	1.6	1
47	Clinical predictors of efficacy for immune checkpoint inhibition in lung cancer patients.. Journal of Clinical Oncology, 2019, 37, e20600-e20600.	1.6	1
48	Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNÎ² and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma.. Journal of Clinical Oncology, 2020, 38, TPS3161-TPS3161.	1.6	1
49	Animated patientâ€™s guide to lung cancer enables shared decisions and improves health outcomes.. Journal of Clinical Oncology, 2021, 39, e18634-e18634.	1.6	0